1-13 of 13
fluorescent in situ hybridization
Close
Sort by
Journal Articles

Roundtable: How I treat a newly diagnosed patient with high-risk myeloma

Jonathan L. Kaufman
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 120–124.
https://doi.org/10.1182/hematology.2019000015
Published: 2019
Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.
https://doi.org/10.1182/hematology.2019000075
Published: 2019
Journal Articles

Current treatment of double hit and double expressor lymphoma

Patrick M. Reagan, Andrew Davies
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 295–297.
https://doi.org/10.1182/asheducation-2017.1.295
Published: 2017
Journal Articles

Safety profiles of novel agent therapies in CLL

Inhye E. Ahn, Matthew S. Davids
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 354–357.
https://doi.org/10.1182/asheducation-2017.1.354
Published: 2017
Journal Articles

First-line therapy for young patients with CLL

Nitin Jain, Susan O’Brien
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 146–148.
https://doi.org/10.1182/asheducation-2016.1.146
Published: 2016
Journal Articles

Molecular monitoring in CML and the prospects for treatment-free remissions

Michael W. Deininger
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 257–263.
https://doi.org/10.1182/asheducation-2015.1.257
Published: 2015
Journal Articles

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Clive S. Zent, W. Richard Burack
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 119–124.
https://doi.org/10.1182/asheducation-2014.1.119
Published: 2014
Journal Articles

Evidence-Based Mini-Review: The Role of Alkylating Agents in the Initial Treatment of Chronic Lymphocytic Leukemia Patients with the 11q Deletion

Wei Ding, Alessandra Ferrajoli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 90–92.
https://doi.org/10.1182/asheducation-2010.1.90
Published: 2010
Journal Articles

Ultra High-Risk Myeloma

Hervé Avet-Loiseau
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 489–493.
https://doi.org/10.1182/asheducation-2010.1.489
Published: 2010
Journal Articles

Predicting clinical outcome in CLL: how and why

Tait D. Shanafelt
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 421–429.
https://doi.org/10.1182/asheducation-2009.1.421
Published: 2009
Journal Articles

Molecular Profiling in CLL

John G. Gribben
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 444–449.
https://doi.org/10.1182/asheducation-2008.1.444
Published: 2008
Journal Articles

Investigative Tools for Diagnosis and Management

Nikhil C. Munshi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 298–305.
https://doi.org/10.1182/asheducation-2008.1.298
Published: 2008
Journal Articles

Chronic Lymphocytic Leukemia: Case-Based Session

Kanti R. Rai, Hartmut Döhner, Michael J. Keating, Emili Montserrat
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2001) 2001 (1): 140–156.
https://doi.org/10.1182/asheducation-2001.1.140
Published: 2001